BIO News and Press, Bio-Rad Laboratories Inc. Class A From 07/11/22

The investment case for Bio-Rad hinges almost entirely on performance of its key equity holding, Sartorius AG. Findings show the deep causal relationship between the pair and how a breakdown of this has contributed to heavy losses in FY22. Technical momentum is weak and investors ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its inaugural corporate sustainability report. The report is based on an assessment Bio-Rad conducted in 2021 to identify the highest priority t...

Waters Corporation has followed the broader market lower, even as the company shows some attractive financial results. Long term, the picture for the business will likely be favorable, but this doesn't change the fact that there are more appealing opportunities to be had. This is ...

Citi says investors should still be looking for quality stocks when dealing with the Fed rate hike cycle and a possible recession. "Admittedly, stocks with high-quality attributes have not been immune from this year’s volatility," equity strategist Scott Chronert wrote in a note. "Why?...

PerkinElmer has experienced significant growth over the past few years, admittedly with some of it being temporary because of the pandemic. This year should be weaker than last year was, but the overall fundamental condition for the enterprise is solid. Add in that shares look att...

BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...

BofA strategists have names for investors looking to put cash back to work after the 2022 selloff. The equity strategy teams highlighted two Buy the Dip screens this week. Beaten-down tech "Tech and Growth stocks have been the biggest laggards YTD amid a hawkish Fed," strategist Savita Subram...

Bio-Rad Laboratories, Inc. (BIO) Q1 2022 Earnings Conference Call April 28, 2022 06:00 PM ET Company Participants Ed Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon...

Bio-Rad Labs press release (NYSE:BIO): Q1 Non-GAAP EPS of $4.94 beats by $1.83. Revenue of $700.1M (-3.7% Y/Y) beats by $22.1M. COVID-related revenue was approximately $45 million in the first quarter of 2022 versus $94 million in the year ago period. Excluding COVID-related sales, revenue in...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2022. First-quarter 2022 net sales were $700.1 million, a decrease of 3.7 percent compa...